Cipla's Stock Sees Temporary Dip, But Still Performing Well with 'Buy' Call from MarketsMOJO

Oct 10 2024 01:50 PM IST
share
Share Via
Despite underperforming the Sensex in the short term, Cipla's stock remains above its moving averages and has shown a possible trend reversal after three days of gains. Cipla, a leading pharmaceutical company, experienced a -3.2% drop in its stock price on October 10th, 2024, closing at Rs 1630.75. However, this should not worry investors as the stock still has a 4.44% difference from its 52-week high and has outperformed the sector by -1.81%. The stock's moving averages are positive and it has a 'Buy' call from MarketsMojo. Despite underperforming the Sensex in the short term, Cipla's stock remains above its moving averages and has shown a possible trend reversal after three days of gains.

Cipla ., a leading pharmaceutical company in the largecap industry, has recently seen a dip in its stock price. On October 10th, 2024, the company's stock fell by -3.2%, closing at Rs 1630.75. However, this dip should not be a cause for concern for investors, as MarketsMOJO has given a 'Buy' call for the stock.

Despite the recent drop, Cipla's stock is still performing well, with a 4.44% difference from its 52-week high of Rs 1702. The stock has also outperformed the sector by -1.81% today. It is worth noting that this drop comes after three consecutive days of gains for the stock, indicating a possible trend reversal.

On the intraday front, Cipla's stock touched a low of Rs 1623.4, a decrease of -3.43%. However, the stock's moving averages are still positive, with it being higher than the 50-day, 100-day, and 200-day moving averages. It is only lower than the 5-day and 20-day moving averages.

In comparison to the Sensex, Cipla's stock has underperformed in the past day and month, with a -3.26% and -0.57% difference, respectively. However, the Sensex has also seen a slight decrease in performance during the same time periods.

Overall, Cipla's stock may have seen a dip, but it is still performing well and has a 'Buy' call from MarketsMOJO. Investors should not be discouraged by this temporary drop and can continue to have confidence in the company's growth in the pharmaceutical industry.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News